Medical Device Batteries Market

The global medical device batteries market size was USD 2.10 Billion in 2025 and is expected to register a revenue CAGR of 9.1% during the forecast period. Market revenue growth is supported by continued demand for implantable cardiac and neuromodulation devices, with Integer Holdings, the industry's largest disclosed medical device contract development and manufacturing organisation, reporting full-year 2025 sales of USD 1.85 billion, up 8% year on year, across a portfolio that includes pacemaker batteries, implantable and external batteries, and specialised batteries for cardiac rhythm management, neuromodulation and portable medical applications. Integer's Cardio & Vascular segment reached USD 284 million in the fourth quarter of 2025, up 11% year on year and now representing 60% of the company's total revenue, reflecting the company's strategic shift toward higher-growth interventional and structural heart markets. These are some of the key factors driving revenue growth of the market.

Lithium/iodine primary battery manufacturers, lithium/silver vanadium oxide primary battery manufacturers, and lithium-ion rechargeable battery manufacturers are the commercial categories that constitute the medical device batteries market, with cardiac rhythm management devices, neuromodulation devices, and portable and external medical equipment the primary demand sources. Integer traces its implantable battery lineage to 1958, when Wilson Greatbatch invented the implantable pacemaker battery, and the company introduced lithium/iodine batteries for pacemakers in the early 1970s that remain the principal power source for standard pacemakers today, providing up to 12 years of device life under certain conditions with high reliability and predictability. For applications requiring higher power, the company introduced lithium/silver vanadium oxide batteries for implantable cardioverter defibrillators in the mid-1980s, which have demonstrated five-year battery life in certain device designs.

However, Integer's Cardiac Rhythm Management & Neuromodulation segment declined 2% year on year to USD 167 million in the fourth quarter of 2025, primarily due to lower demand from select emerging customers with products approved under the FDA's premarket approval pathway, illustrating that implantable device battery demand is exposed to individual customer product cycles and adoption timelines that do not move in lockstep with broader medical device market growth. Switching costs in the category remain a double-edged constraint: while they protect incumbent battery suppliers once a device receives regulatory approval, they also mean new battery chemistry or supplier qualification cycles are lengthy and expensive for OEMs to pursue, slowing the pace at which newer rechargeable lithium-ion platforms can displace decades-established primary cell chemistries even where technically superior. These factors substantially limit medical device batteries market growth over the forecast period.

Based on chemistry, the global medical device batteries market is segmented into lithium/iodine, lithium/silver vanadium oxide, lithium-ion rechargeable, and other primary chemistries. The lithium/iodine segment commands the largest revenue share because it remains the principal power source for standard pacemakers, a device category with the largest installed implant volume of any cardiac rhythm management product, and Integer Holdings states that lithium batteries using this chemistry, manufactured both by the company and by others under license from its technology, provide up to 12 years of device life with high reliability and predictability that has made it the industry standard since its introduction in the early 1970s.

The lithium-ion rechargeable segment is expected to register the fastest revenue growth rate in the global medical device batteries market over the forecast period, from a smaller base than established primary cell chemistries. Integer's Xcellion lithium-ion secondary rechargeable cells are positioned as the power source of choice for implantable neuromodulation and circulatory support devices, including left ventricular assist devices, where application energy demands exceed the practical limits of primary batteries, a growing category as neuromodulation device adoption expands beyond traditional cardiac rhythm management into pain management, movement disorder and other emerging therapeutic applications.

• 01What is the global medical device batteries market size in 2025 and what CAGR is expected during 2026-2035?
• 02What full-year 2025 revenue did Integer Holdings report, and how did its Cardio & Vascular segment perform?
• 03Why did Integer Holdings' Cardiac Rhythm Management & Neuromodulation segment decline in the fourth quarter of 2025?
• 04Who invented the implantable pacemaker battery, and when did lithium/iodine chemistry become the industry standard?
• 05What is Integer's Xcellion lithium-ion rechargeable platform, and which applications does it target?
• 06Why does the lithium/iodine segment account for the largest chemistry revenue share in the global medical device batteries market?
• 07Why does the lithium-ion rechargeable segment register the fastest revenue growth rate in the global medical device batteries market over the forecast period?
• 08What acquisitions did Integer Holdings complete in 2024 and 2025, and how do they expand its capabilities?
• 09Why do switching costs protect incumbent medical device battery suppliers, and how does that affect new chemistry adoption?
• 10Why does North America lead the global medical device batteries market by 2025 revenue share?

This report covers the global medical device batteries market across all major segments and geographic regions. Primary research combines panel conversations with industry experts and is cross-referenced against company annual reports and government agency data. All market size figures use 2025 as the base year with a 2026-2035 forecast period.